Biopharma companies face a complex journey as they strive to transform groundbreaking ideas into life-saving therapeutics. The process is fraught with challenges, also driven by current geopolitical changes. This playbook explores how CDMOs can help.
Grants NIT an exclusive license to all rights to market, sell and distribute Endari and any generic equivalents in sickle cell disease in the U.S., its territories and Canada.
Will integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D and commercialization to accelerate the development of cancer therapies.
GenVault is a biorepository designed from the ground up to meet the highest standard of security and compliance for your sample needs. We provide GxP climate-controlled storage solutions, transport services, and stability chamber units. Our multi-level vertically structured facility is located close to global transportation hubs in the Greater Philadelphia area.
Founded in 2014, UBI Pharma Inc. leads in sterile injectable manufacturing in Taiwan. We take pride in being routinely inspected by US FDA, Japan PMDA, UK MHRA and more. With proven track record and extensive expertise, we offer one-stop shop CDMO/CMO services, to transform your idea into commercialized product rapidly without compromising quality.
